AHFS Drug Information 2026

9781585287772

Paperback / softback, published 28 February 2026

3504 pages
27.9 x 21.7 x 8 cm, 3.71 kg

“AHFS DI has maintained itself as a premier, evidence-based drug compendium. Even in the era of digital, online use, AHFS DI has evolved...and offers its information both in print and online. What sets AHFS DI apart from the [other drug information books available] is its comparative, unbiased, evaluative drug information and its continually maintained relevance. It has been vetted through multiple channels of review and has consistently been recognized as the gold standard of where to obtain drug information.” —Patrick J. Scoble, PharmD, Doodys Review Service

""This book succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field. This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners. The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well."" —Melissa M. Potts, BS, PharmD, Doodys Review Service

AHFS Drug Information® 2026 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.

Updates in the new edition:

• Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
• Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
• Contemporary topics such as biosimilars, novel orphan drugs, and updated vaccine guidance based on recommendations from the CDC’s Advisory Committee on Immunization Practices (ACIP) and other authoritative organizations
• Essential drug information content for patient safety including FDA Medwatch alerts, Standardize4Safety concentrations for IV and oral liquid medications, ISMP recommendations, REMS data, BEERS criteria, boxed warnings, and focused updates based on FDA safety findings
• Pharmacogenomic considerations in drug dosing and selection
• Expanded content on new and emerging gene and cellular therapies
• Class-wide revisions to standard and established therapies for common disease states including hypertension and diabetes
• Expanded content on off-label uses, real world data, and long-term clinical data
• New content on new molecular entities (NMEs) and biologic approvals
• New oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee